Clinical trials: Cancer of the Esophagus
Esophageal Squamous Cell Carcinoma
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
This Phase I study is to determine the maximum tolerated fraction dose (MTD) for split-course hypo-CCRT following induction chemo-immunotherapy in LA-ESCC patients, to clarify the dosimetric advantage of split-course hypo-CCRT…
- Trial name
- NCT06020885
- Testing
- Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Hypoxemia, Esophageal Cancer
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
Hypoxaemia during sedated gastrointestinal endoscopy exceeds 40 % in morbidly obese (BMI ≥ 35 kg m-²) patients. High-flow nasal cannula alone often fails because of persistent airway collapse.
- Conditions
- Hypoxemia, Esophageal Cancer, Morbidly Obese Patients, Gastric Cancer
- Trial name
- NCT07175155
- Testing
- COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation, High-Flow Nasal Cannula Oxygenation
- Where
- 5 sites in China
- Volunteers
- 410 people
- Sponsor
- Zhejiang University
Esophageal Cancer, Esophageal Carcinoma
Effect of Feeding Jejunostomy on Sarcopenia in Patients With Esophageal Cancer
Participants were diagnosed with esophageal cancer needing chemo- or radiochemotherapy before the potentially curing surgery consisting of esophagectomy.
- Conditions
- Esophageal Cancer, Esophageal Carcinoma, Sarcopenia, Feeding Tube
- Trial name
- NCT06712706
- Testing
- Feeding jejunostomy placement, Feeding jejunostomy placement at esophagectomy
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Stefan Gutknecht
Colorectal Cancer, Esophagus Cancer
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
This is a single-arm clinical trial to evaluate the feasibility of a chemotherapy regimen using adaptive, individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose.
- Conditions
- Colorectal Cancer, Esophagus Cancer, Appendix Cancer, Small Bowel Cancer
- Trial name
- NCT05780684
- Testing
- FOX dose-escalation algorithm
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Esophageal Cancer
Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (TPF) in Pre-treated patients…
- Trial name
- NCT00209716
- Testing
- Taxotere, 5-Fluorouracil, Briplatin
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Esophageal Neoplasms, Esophageal Diseases
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal…
- Conditions
- Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms
- Trial name
- NCT05624099
- Testing
- camrelizumab, Paclitaxel drugs, Platinum drug
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma
This is an open-label, multi-center, single arm study to evaluate the efficacy, safety and tolerability of KN046 in subjects with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT03925870
- Testing
- KN046
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Esophageal Cancer Stage IIB, Esophageal Cancer Stage III
Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC
This is a Phase III clinical trail which Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy with Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer.
- Trial name
- NCT03366883
- Testing
- Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the…
- Conditions
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma
- Trial name
- FAST (NCT01630083)
- Testing
- epirubicin, oxaliplatin, capecitabine
- Where
- 48 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 252 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non-small Cell Lung Cancer, Colorectal Cancer
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04121286
- Testing
- JAB-3312
- Where
- 5 sites in China
- Volunteers
- 17 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Gastric Cancer (GC), Premalignant Lesion
AI-Based Risk Prediction Model for Upper Digestive Tract Cancer
Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development.
- Conditions
- Gastric Cancer (GC), Premalignant Lesion, Gastric Intestinal Metaplasia, Atrophic Gastritis
- Trial name
- NCT07605312
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Esophageal Cancer, Gastric Cancer
Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with locally…
- Trial name
- NCT00003192
- Testing
- aminocamptothecin
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Chicago
Bladder Cancer, Brain and Central Nervous System Tumors
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer
- Trial name
- NCT00313599
- Testing
- lapatinib, paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Esophageal Cancer, Chemoradiotherapy
Chemoradiotherapy in Unresectable Esophageal Cancer
This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional…
- Conditions
- Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm
- Trial name
- NCT04278287
- Testing
- Radiotherapy, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 5 sites in China
- Volunteers
- 105 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Esophagus, Pancreatic Cancer
Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery
Every patient undergoing surgery in the abdomen will experience temporary paralysis of bowel function. This study evaluates whether chewing gum can reduce the bowel paralysis after surgery in patients undergoing either esophageal…
- Trial name
- NCT02260128
- Testing
- Chewing gum
- Where
- Denmark
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Michael Bau Mortensen
The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection)
Prediction Models for Complications After CRT in Esophageal Cancer
The aim of this project is to develop and validate NTCP-models for complications after nCRT (and surgical resection), that can be uses for model-based dose optimization for PhRT and PRT, and for model-based selection for PRT, in…
- Trial name
- MODELS (NCT06366828)
- Testing
- retrospective
- Where
- 8 sites in Netherlands
- Volunteers
- 2,000 people
- Sponsor
- University Medical Center Groningen
Resecable Esophageal or Gastroesophageal Junction Cancer
Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer
Esophageal and gastroesophageal junction cancers remain associated with poor survival despite progress in multimodal treatment. Surgery, especially Ivor-Lewis esophagectomy, combined with peri-operative therapy improves survival…
- Trial name
- MIRO-2 (NCT07408999)
- Testing
- Totally Minimally Invasive Esophagectomy (TMIE), Hybrid Esophagectomy (HE)
- Where
- France
- Volunteers
- 327 people
- Sponsor
- University Hospital, Lille
Stage II Esophageal Cancer, Stage III Esophageal Cancer
A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer
Neoadjuvant chemoradiotherapy(Neo-CRT) plus surgery has been regarded as a standard of care for patients with resectable locally advanced oesophageal cancer.
- Trial name
- NCT02959385
- Testing
- Definitive Radiochemotherapy, Neoadjuvant Radiochemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Barrett Esophagus, Esophageal Cancer
Microbiome Involvement With Barrett's Esophagus and Progression to Esophageal Adenocarcinoma
This study will examine the hypothesis that altered esophageal microbiome leads to the development of esophageal adenocarcinoma (EAC).
- Trial name
- NCT03216135
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ochsner Health System
Esophageal Cancer
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.
- Trial name
- NCT00400114
- Testing
- Irinotecan, Cisplatin, Radiation
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.